Biotech Adam Feuerstein STAT Plus: FDA approves first gene therapy targeting rare form of inherited blindness
Adam's Take Adam Feuerstein STAT Plus: Spark Therapeutics’s success is lifting all gene therapy stocks even though risks remain
Biotech Adam Feuerstein STAT Plus: Spark’s novel gene therapy for blindness is racing to a historic date with the FDA
Pharmalot Ed Silverman STAT Plus: Pharmalot, Pharmalittle: Feds probe Sun Pharma over generic pricing
The Pharmalot View Ed Silverman To get over sticker shock, new payment models are needed for gene therapies
